BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, Somasunderam A, Utay NS. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. Clin Transl Sci. 2016;9:139-148. [PMID: 27169903 DOI: 10.1111/cts.12397] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
2 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Reference Citation Analysis]
3 Palmieri B, Corazzari V, Panariello Brasile DG, Sangiovanni V, VadalÀ M. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterol Dietol 2020;66:307-20. [PMID: 33443240 DOI: 10.23736/S1121-421X.20.02738-5] [Reference Citation Analysis]
4 Östlund C, Hernandez-Ono A, Shin JY. The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD. Biology (Basel) 2020;9:E338. [PMID: 33076344 DOI: 10.3390/biology9100338] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Qi B, Fang Q, Liu S, Hou W, Li J, Huang Y, Shi J. Advances of CCR5 antagonists: From small molecules to macromolecules. Eur J Med Chem 2020;208:112819. [PMID: 32947226 DOI: 10.1016/j.ejmech.2020.112819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology 2020;72:892-905. [PMID: 31943293 DOI: 10.1002/hep.31108] [Cited by in Crossref: 113] [Cited by in F6Publishing: 114] [Article Influence: 56.5] [Reference Citation Analysis]
7 Diaz Soto MP, Lim JK. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. Hepat Med 2020;12:115-23. [PMID: 32884369 DOI: 10.2147/HMER.S230613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev Syst Biol Med. 2020;e1499. [PMID: 32713091 DOI: 10.1002/wsbm.1499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
9 Doulberis M, Papadimitriou K, Papaefthymiou A, Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 2020;1:170-83. [DOI: 10.37349/emed.2020.00012] [Reference Citation Analysis]
10 Yang Y, Zhao Y, Li W, Wu Y, Wang X, Wang Y, Liu T, Ye T, Xie Y, Cheng Z, He J, Bai P, Zhang Y, Ouyang L. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. Eur J Med Chem 2020;197:112311. [PMID: 32339855 DOI: 10.1016/j.ejmech.2020.112311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 151] [Article Influence: 24.5] [Reference Citation Analysis]
12 Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs 2020;29:89-92. [PMID: 31952447 DOI: 10.1080/13543784.2020.1718106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
13 Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol 2020;16:11-30. [PMID: 31903790 DOI: 10.1080/17425255.2020.1711884] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
14 Brummer G, Fang W, Smart C, Zinda B, Alissa N, Berkland C, Miller D, Cheng N. CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments. Oncogene 2020;39:2275-89. [PMID: 31827233 DOI: 10.1038/s41388-019-1141-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
15 Santoro R, Mangia A. Progress in promising anti-fibrotic therapies. Expert Rev Gastroenterol Hepatol 2019;13:1145-52. [PMID: 31692390 DOI: 10.1080/17474124.2019.1688659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Dilly Penchala S, Alagaratnam J, Challenger E, Amara A, Else L, Winston A, Khoo S. The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. Biomed Chromatogr 2020;34:e4711. [PMID: 31629375 DOI: 10.1002/bmc.4711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zhangdi HJ, Su SB, Wang F, Liang ZY, Yan YD, Qin SY, Jiang HX. Crosstalk network among multiple inflammatory mediators in liver fibrosis. World J Gastroenterol 2019; 25(33): 4835-4849 [PMID: 31543677 DOI: 10.3748/wjg.v25.i33.4835] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
19 Abid S, Marcos E, Parpaleix A, Amsellem V, Breau M, Houssaini A, Vienney N, Lefevre M, Derumeaux G, Evans S, Hubeau C, Delcroix M, Quarck R, Adnot S, Lipskaia L. CCR2/CCR5-mediated macrophage–smooth muscle cell crosstalk in pulmonary hypertension. Eur Respir J 2019;54:1802308. [DOI: 10.1183/13993003.02308-2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
20 Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. 2018;15:555-567. [PMID: 29844586 DOI: 10.1038/s41575-018-0020-y] [Cited by in Crossref: 149] [Cited by in F6Publishing: 144] [Article Influence: 49.7] [Reference Citation Analysis]
21 Vonghia L, Van Herck MA, Weyler J, Francque S. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. Front Immunol 2019;10:563. [PMID: 30972062 DOI: 10.3389/fimmu.2019.00563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
22 Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018;20:315-329. [PMID: 29740791 DOI: 10.1007/s40272-018-0292-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 Argyle D, Kitamura T. Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. Front Immunol. 2018;9:2629. [PMID: 30483271 DOI: 10.3389/fimmu.2018.02629] [Cited by in Crossref: 52] [Cited by in F6Publishing: 78] [Article Influence: 13.0] [Reference Citation Analysis]
24 Reuveni D, Gore Y, Leung PSC, Lichter Y, Moshkovits I, Kaminitz A, Brazowski E, Lefebvre E, Vig P, Varol C, Halpern Z, Shibolet O, Gershwin ME, Zigmond E. The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis. Front Immunol 2018;9:1852. [PMID: 30158929 DOI: 10.3389/fimmu.2018.01852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
25 D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol 2018;104:1241-52. [PMID: 30088682 DOI: 10.1002/JLB.5A0817-328RRR] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res 2018;134:289-98. [PMID: 30021122 DOI: 10.1016/j.phrs.2018.07.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
27 Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018;67:1754-67. [PMID: 28833331 DOI: 10.1002/hep.29477] [Cited by in Crossref: 374] [Cited by in F6Publishing: 360] [Article Influence: 93.5] [Reference Citation Analysis]
28 Zhou X, Moore BB. Location or origin? What is critical for macrophage propagation of lung fibrosis? Eur Respir J 2018;51:1800103. [PMID: 29496789 DOI: 10.1183/13993003.00103-2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
29 Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27:301-311. [PMID: 29448843 DOI: 10.1080/13543784.2018.1442436] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
30 Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. Journal of Hepatology 2018;68:362-75. [DOI: 10.1016/j.jhep.2017.10.015] [Cited by in Crossref: 139] [Cited by in F6Publishing: 130] [Article Influence: 34.8] [Reference Citation Analysis]
31 Pérez-Martínez L, Ochoa-Callejero L, Rubio-Mediavilla S, Narro J, Bernardo I, Oteo JA, Blanco JR. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. Transl Res 2018;196:17-30. [PMID: 29421523 DOI: 10.1016/j.trsl.2018.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Huh JH, Kim HM, Lee ES, Kwon MH, Lee BR, Ko HJ, Chung CH. Dual CCR2/5 Antagonist Attenuates Obesity-Induced Insulin Resistance by Regulating Macrophage Recruitment and M1/M2 Status. Obesity (Silver Spring) 2018;26:378-86. [PMID: 29280303 DOI: 10.1002/oby.22103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
33 Czaja AJ. Evolving paradigm of treatment for autoimmune hepatitis. Expert Review of Clinical Immunology 2017;13:781-98. [DOI: 10.1080/1744666x.2017.1319764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
34 Bansal R, Nagórniewicz B, Prakash J. Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm 2016;2016:7629724. [PMID: 27999454 DOI: 10.1155/2016/7629724] [Cited by in Crossref: 48] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
35 Ilan Y. Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Aliment Pharmacol Ther 2016;44:1168-82. [PMID: 27778363 DOI: 10.1111/apt.13833] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
36 Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016;22:327-335. [PMID: 27729634 DOI: 10.3350/cmh.2016.0049] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
37 Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11:e0158156. [PMID: 27347680 DOI: 10.1371/journal.pone.0158156] [Cited by in Crossref: 160] [Cited by in F6Publishing: 177] [Article Influence: 26.7] [Reference Citation Analysis]